文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛儿科与产科急症

儿童体外循环后不良肺损伤的生物标志物

Biomarkers for Adverse Lung Injury Following Pediatric Cardiopulmonary Bypass.
PubMed 文献 · Crit Care Explor · 2021-09-07
一句话结论回顾性蛋白质组学研究提示,儿童体外循环术后多种血浆蛋白与不良呼吸结局相关,术前及术后早期标志物可能反映不同病理机制。

该回顾性队列研究对接受体外循环心脏手术的婴儿(STS-EACTS 3或4级)进行血浆蛋白质组学分析,比较术后机械通气>48小时组与<48小时组。蛋白聚糖4在独立样本(每组n=20)中验证,术后水平显著低于对照组(128±67 vs 195±160 ng/mL,P=0.037)。术前标志物可能提示风险因素,术后标志物可能反映持续病理过程。

要点

  • 术后0小时和48小时分别有18种和25种蛋白差异表达,涉及细胞骨架重塑、免疫反应和凝血通路。
  • 蛋白聚糖4在独立样本中验证,术后水平在长时间通气组显著降低(128±67 vs 195±160 ng/mL,P=0.037)。
  • 术前差异蛋白(如tenascin升高、tetranectin降低)可能与凝血异常等术前风险因素相关。
  • 术后早期差异蛋白(如血红蛋白β升高、C8β降低)可能反映ongoing病理生物学机制。

适用人群与场景

  • 接受体外循环心脏手术的婴儿,手术复杂度为STS-EACTS 3或4级。
  • 研究组为术后机械通气>48小时患者,对照组为术后机械通气<48小时患者,两组在体重、年龄和体外循环时长上匹配。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性病历回顾研究,单中心,样本量小(蛋白质组学分析4例对照组和4例研究组,验证队列每组n=20)。
  • 干预:无。
  • 关键验证:蛋白聚糖4在独立样本中验证,研究组显著低于对照组(128±67 vs 195±160 ng/mL,P=0.037)。
  • 通路分析:最显著通路为细胞骨架重塑,其他涉及免疫反应和凝血。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(蛋白质组学分析)。
  • 证据等级:原文未提及。
  • 局限:单中心、回顾性、样本量小(蛋白质组学分析仅4例/组),验证队列样本量有限(每组n=20),无干预,结果需前瞻性验证。

对床旁实践的改变

  • 原文未提及

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Cardiopulmonary bypass triggers systemic inflammation, resulting in lung injury, and frequently leads to prolonged mechanical ventilation. Biomarkers of systemic inflammation are required to predict the risk of such complications. We hypothesize that specific serum proteins can be used as biomarkers to predict the severity of lung injury following cardiac surgery.

DESIGN: Retrospective chart review study.

SETTING: Clinical variables were collected and used in conjuncture with unbiased proteomic analysis using mass spectrometry that was performed on frozen plasma samples from a study group (patients with mechanical ventilation > 48 hr post surgery) and a control group (patients with mechanical ventilation < 48 hr post surgery).

SUBJECTS: Subjects included were infants who underwent cardiac surgery with similar complexity (Society of Thoracic Surgeons-European Association for Cardiothoracic Surgery 3 or 4) using cardiopulmonary bypass. Patients in both groups were matched for their weight, age, and duration of cardiopulmonary bypass.

MEASUREMENTS AND MAIN RESULTS: Four-hundred eighty-three proteins were identified (99% minimum confidence and two peptides minimum, protein false discovery rate 0.1%) on proteomic analysis of four control and four study patients at precardiopulmonary bypass, 0, and 48 hours postcardiopulmonary bypass samples. Thirty-six of 178 proteins were significantly different (≥ 1.5-fold; p < 0.05) at precardiopulmonary bypass (top increased: tenascin; top decreased: tetranectin), 18 of 140 proteins at 0 hour (top increased: hemoglobin beta; top decreased: C8 beta), and 25 of 166 proteins at 48 hours post surgery (top increased: proteoglycan 4; top decreased: galectin-3-binding protein). The top pathway involved cytoskeleton remodeling. Other pathways involved immune response and blood coagulation. Proteoglycan 4 was validated by enzyme-linked immunosorbent assay in a different set of samples (n = 20/group; mean ± sd: 128 ± 67 vs 195 ± 160 ng/mL) (p = 0.037).

CONCLUSIONS: Multiple proteomic biomarkers were associated with worse respiratory outcomes. Precardiopulmonary bypass biomarkers might indicate risk factors (e.g., abnormalities of coagulation), whereas those identified at 0 hour and post cardiopulmonary bypass may reflect mechanisms of ongoing pathobiology.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Asfari A, Hock KM, Byrnes JW, et al. Biomarkers for Adverse Lung Injury Following Pediatric Cardiopulmonary Bypass. Crit Care Explor. 2021. PMID: 34514425. doi:10.1097/CCE.0000000000000528

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。